Darzalex combo OK’d for multiple myeloma transplant-eligible patients
The subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) has…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreThe subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) has…
Johnson & Johnson (J&J) is asking regulatory authorities…
Real-world treatment with the cell therapy Carvykti (ciltacabtagene autoleucel)…
Johnson & Johnson (J&J) is seeking U.S. Food…
A single infusion of the cell therapy Carvykti (ciltacabtagene…
The U.S. Food and Drug Administration has approved Sanofi’s…